Voxel's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 77.78.
Voxel's Days Inventory for the
three
months ended in Mar. 2026 was 20.5.
Voxel's Days Payable for the
three
months ended in Mar. 2026 was 47.35.
Therefore, Voxel's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 50.93.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Voxel Cash Conversion Cycle Related Terms
Voxel Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Voxel's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QDB vs TMO, DHR, IDXX: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Voxel's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voxel Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Voxel's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Voxel's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Voxel's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voxel (LTS:0QDB) has a Cash Conversion Cycle of 50.93 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Voxel and its competitors.
Is Voxel's Cash Conversion Cycle too high?
Voxel's current Cash Conversion Cycle is 50.93. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 74.74. Voxel's value of 50.93 is 31.9% below this industry median. Overall, Voxel has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Voxel's Cash Conversion Cycle compare to TMO and DHR?
Voxel's Cash Conversion Cycle of 50.93 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 74.74. Voxel's value of 50.93 is 31.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 74.74, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voxel's current Cash Conversion Cycle of 50.93 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Voxel and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 74.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voxel's current Cash Conversion Cycle is 50.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voxel stock overvalued right now?
Voxel (LTS:0QDB) has a current Cash Conversion Cycle of 50.93. The stock's GF Value™ is zł128.03, compared to a current price of zł109.00 — trading 14.9% below its estimated fair value. The current Cash Conversion Cycle is 50.93 and 31.9% below the Medical Diagnostics & Research industry median of 74.74. Voxel's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Voxel (LTS:0QDB), the current Cash Conversion Cycle is 50.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voxel (LTS:0QDB) Overvalued in 2026?
Based on GuruFocus' analysis, Voxel stock appears to be undervalued.
The current stock price of zł109.00 is trading 14.9% below its estimated GF Value™ of zł128.03.
Key valuation signals for LTS:0QDB:
Cash Conversion Cycle: 50.93
GF Value™: zł128.03 vs. price of zł109.00 (14.9% below fair value)
Industry Position: 31.9% below the Medical Diagnostics & Research median
No single metric tells the full story. See the LTS:0QDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voxel SA is a network of diagnostic imaging laboratories created for patients and to increase access to high-quality tests. The company operates diagnostic imaging centers and laboratories and provides several services such as magnetic resonance imaging, computed tomography and positron emission tomography. It has 33 specialised laboratories in 21 cities throughout Poland.
97GF Score
Get the complete analysis for LTS:0QDB
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QDB has been successfully added to your 
